查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1211005

难治性抑郁症 (TRD) 治疗的全球市场规模和预测：按药物类型、分销渠道和地区分析，2022-2029 年

Global Treatment-resistant Depression Treatment Market Size study & Forecast, by Drug Type, by Distribution Channel and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021 年全球难治性抑郁症治疗市场价值约 15.2 亿美元，预计在 2022-2029 年预测期内将以超过 9.0% 的健康增长率增长。

难治性抑郁症 (TRD) 是重度抑郁症 (MDD) 的一种形式，是由于在治疗过程中对至少两种抗抑郁药的反应不当所致。 炎症系统的激活、神经递质功能障碍、异常的神经元活动、忧郁的临床特征、双极性和较高的创伤负荷是与这种疾病相关的一些病症。 与口服给药相比，对其他给药途径的偏好增加、药物开发项目数量增加以及医疗成本上升是推动全球市场需求的主要因素。

这种情绪障碍的患病率上升是促进市场增长的关键因素。 当两种抗抑郁药服用足够长的时间（通常为 6 週）并且没有反应时，就会发生 TRD。 这种疾病患病率的增加导致对难治性抑郁症的治疗需求增加。 Springer 报告说，到 2021 年 8 月，全球将有超过 3 亿人患有重度抑郁症，其中超过三分之一的人患有难治性抑郁症。我知道这一点。 因此，不断增加的疾病负担是市场增长的催化剂。 此外，在预测期内，市场主要参与者对研发活动的投资增加和举措不断增加，带来了各种有利可图的机会。 然而，有限的治疗途径以及对这种情绪障碍患者的诊断和管理指南缺乏明确性限制了整个 2022-2029 年预测期内的市场增长。

全球难治性抑郁症治疗市场研究考虑的主要区域是亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于指南的增加、药物批准、研发的大量投资以及市场参与者的关注度增加，北美在收入方面占据了市场主导地位。 另一方面，由于患有难治性抑郁症的患者数量增加以及市场空间中对情绪障碍治疗相关意识的提高等因素，预计亚太地区在预测期内将以最高复合年增长率增长。增加。

这项研究的目的是定义近年来各个细分市场和国家的市场规模，并预测未来几年的价值。 该报告旨在捕捉被调查国家工业的定性和定量方面。

它还提供了关键方面的详细信息，例如决定市场未来增长的驱动因素和挑战。 此外，它还包含供利益相关者投资的微观市场潜在机会，以及对主要参与者的竞争格局和产品供应的深入分析。

内容

第 1 章执行摘要

  • 市场概况
  • 2019-2029 年各细分市场的全球市场估计和预测
    • 难治性抑郁症治疗市场：按地区划分，2019-2029 年
    • 难治性抑郁症治疗市场：按药物类型分类，2019-2029 年
    • 抗抑郁药物市场：按分销渠道，2019-2029 年
  • 主要趋势
  • 调查方法
  • 调查先决条件

第 2 章难治性抑郁症的全球市场定义和范围

  • 调查的目的
  • 市场定义和范围
    • 调查范围
    • 工业发展
  • 调查年份
  • 货币兑换率

第 3 章难治性抑郁症的全球市场动态

  • 抗抑郁药市场影响分析 (2019-2029)
    • 市场驱动因素
      • 难治性抑郁症患病率上升
      • 增加药物开发项目
    • 市场挑战
      • 有限的治疗选择
      • 缺乏针对这种情绪障碍患者的明确诊断和管理指南
    • 市场机会
      • 增加对研发活动的投资
      • 主要市场进入者的举措增加

第 4 章全球难治性抑郁症治疗市场行业分析

  • 波特 5 力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 波特 5 力模型的未来方法 (2019-2029)
  • 害虫分析
    • 政治
    • 经济的
    • 社交
    • 技术
  • 顶级投资机会
  • 关键成功策略
  • 行业专家的展望
  • 分析师的结论和建议

第 5 章风险评估：COVID-19 的影响

  • 评估 COVID-19 对行业的总体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

第 6 章治疗难治性抑郁症的全球市场，按药物类型分列

  • 市场概况
  • 难治性抑郁症治疗的全球市场：按药物类型进行的性能潜力分析
  • 2019-2029 年按药物类型划分的难治性抑郁症治疗全球市场估计和预测
  • 抗抑郁药市场细分分析
    • 国家导弹防御局
    • 抗抑郁药
    • 抗精神病药
    • 其他

第 7 章：治疗难治性抑郁症的全球市场：按分销渠道

  • 市场概况
  • 治疗难治性抑郁症药物的全球市场：按分销渠道进行的性能潜力分析
  • 2019-2029 年全球难治性抑郁症治疗市场、按分销渠道估算和预测
  • 抗抑郁药市场细分分析
    • 医院药房
    • 药店和零售药店
    • 在线药店

第 8 章抗抑郁药物的全球市场：区域分析

  • 抗抑郁药市场，按地区划分的市场概况
  • 北美
    • 美国
      • 2019-2029 年按药物类型估算和预测
      • 2019-2029 年各分销渠道的估计和预测
    • 加拿大
  • 欧洲难治性抑郁症药物市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区难治性抑郁症治疗市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲难治性抑郁症治疗市场概况
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 世界其他地区

第 9 章衝突信息

  • 顶级市场策略
  • 公司简介
    • 礼来公司
      • 主要信息
      • 概览
      • 财务信息（取决于数据可用性）
      • 产品概述
      • 近期趋势
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Janssen Global Services, LLC（Johnson & Johnson Services, Inc.）
    • AbbVie Inc.
    • AstraZeneca Plc
    • H. Lundbeck A/S
    • Sandoz International GmbH（Novartis AG）
    • Par Pharmaceutical（Endo International plc）
    • Otsuka Pharmaceutical Co., Ltd.（Otsuka Holdings Co., Ltd.）

第 10 章研究过程

  • 研究过程
    • 数据挖掘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 调查属性
  • 调查先决条件

Global Treatment-resistant Depression Treatment Market is valued at approximately USD 1.52 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.0% over the forecast period 2022-2029. Treatment-Resistant Depression (TRD) is a variety of Major Depressive Disorder (MDD) that cause due to the improper response of at least two antidepressants in the treatment process. The inflammatory system activation, neurotransmitter dysfunction, abnormal neural activity, melancholic clinical features, bipolarity, and a higher traumatic load are some conditions that are associated with this disorder. The rising inclination towards other routes of administration compared to oral administration, the increasing drug development projects, and increasing healthcare expenditure are some primary factors that are propelling the market demand across the globe.

The rise in the prevalence of this mood disorder is a key factor that is contributing to the market's growth. TRD occurs when a person hasn't reacted to two separate antidepressant doses taken for a sufficient amount of time, typically six weeks. The demand for the treatment of treatment-resistant depression has increased as a result of the rise in the prevalence of this medical disease. Springer reported that in August 2021, there are more than 300 million individuals worldwide suffer from significant depressive disorders, and over one-third of those people have depression that is treatment-resistant depression. Hence, the rising disease burden is a catalyzing factor for the market's growth. Moreover, rising investment in research and development activities, as well as the increasing initiatives by the key market players are presenting various lucrative opportunities over the forecasting years. However, the limited therapeutic measure and lack of clarity in guidelines for diagnosis and management of this mood disorder patients are restricting the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Treatment-resistant Depression Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing number of guidelines and approval of drugs, along with the significant R&D investment and increasing focus of market players. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing patient population suffering from treatment-resistant depressive disorder, as well as increasing awareness related to the treatment of mood disorder in the market space.

Major market players included in this report are:

Eli Lilly and Company

GlaxoSmithKline Plc

Pfizer Inc.

Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)

AbbVie Inc.

AstraZeneca Plc

H. Lundbeck A/S

Sandoz International GmbH (Novartis AG)

Par Pharmaceutical (Endo International plc)

Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Recent Developments in the Market:

  • In August 2022, Merck Sharp & Dohme LLC initiated the clinical trial of its Phase IIa to evaluate the efficacy and safety of the company's MK-1942 among treatment-resistant depression patients.
  • In July 2022, Novartis Pharmaceuticals declared that the company is planning to initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.

Global Treatment-resistant Depression Treatment Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Type, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

NMDA

Antidepressants

Antipsychotics

Others

By Distribution Channel:

Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Treatment-resistant Depression Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Treatment-resistant Depression Treatment Market, by Drug Type, 2019-2029 (USD Billion)
    • 1.2.3. Treatment-resistant Depression Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Treatment-resistant Depression Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Treatment-resistant Depression Treatment Market Dynamics

  • 3.1. Treatment-resistant Depression Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rise in the prevalence of treatment-resistant depression
      • 3.1.1.2. Increasing drug development projects
    • 3.1.2. Market Challenges
      • 3.1.2.1. Limited therapeutic measure
      • 3.1.2.2. Lack of clarity in guidelines for diagnosis and management of this mood disorder patients
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising investment in research and development activities
      • 3.1.3.2. Increasing initiatives by the key market players

Chapter 4. Global Treatment-resistant Depression Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Treatment-resistant Depression Treatment Market, by Drug Type

  • 6.1. Market Snapshot
  • 6.2. Global Treatment-resistant Depression Treatment Market by Drug Type, Performance - Potential Analysis
  • 6.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
  • 6.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
    • 6.4.1. NMDA
    • 6.4.2. Antidepressants
    • 6.4.3. Antipsychotics
    • 6.4.4. Others

Chapter 7. Global Treatment-resistant Depression Treatment Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Treatment-resistant Depression Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 7.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies

Chapter 8. Global Treatment-resistant Depression Treatment Market, Regional Analysis

  • 8.1. Treatment-resistant Depression Treatment Market, Regional Market Snapshot
  • 8.2. North America Treatment-resistant Depression Treatment Market
    • 8.2.1. U.S. Treatment-resistant Depression Treatment Market
      • 8.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Treatment-resistant Depression Treatment Market
  • 8.3. Europe Treatment-resistant Depression Treatment Market Snapshot
    • 8.3.1. U.K. Treatment-resistant Depression Treatment Market
    • 8.3.2. Germany Treatment-resistant Depression Treatment Market
    • 8.3.3. France Treatment-resistant Depression Treatment Market
    • 8.3.4. Spain Treatment-resistant Depression Treatment Market
    • 8.3.5. Italy Treatment-resistant Depression Treatment Market
    • 8.3.6. Rest of Europe Treatment-resistant Depression Treatment Market
  • 8.4. Asia-Pacific Treatment-resistant Depression Treatment Market Snapshot
    • 8.4.1. China Treatment-resistant Depression Treatment Market
    • 8.4.2. India Treatment-resistant Depression Treatment Market
    • 8.4.3. Japan Treatment-resistant Depression Treatment Market
    • 8.4.4. Australia Treatment-resistant Depression Treatment Market
    • 8.4.5. South Korea Treatment-resistant Depression Treatment Market
    • 8.4.6. Rest of Asia Pacific Treatment-resistant Depression Treatment Market
  • 8.5. Latin America Treatment-resistant Depression Treatment Market Snapshot
    • 8.5.1. Brazil Treatment-resistant Depression Treatment Market
    • 8.5.2. Mexico Treatment-resistant Depression Treatment Market
    • 8.5.3. Rest of Latin America Treatment-resistant Depression Treatment Market
  • 8.6. Rest of The World Treatment-resistant Depression Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Eli Lilly and Company
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. GlaxoSmithKline Plc
    • 9.2.3. Pfizer Inc.
    • 9.2.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
    • 9.2.5. AbbVie Inc.
    • 9.2.6. AstraZeneca Plc
    • 9.2.7. H. Lundbeck A/S
    • 9.2.8. Sandoz International GmbH (Novartis AG)
    • 9.2.9. Par Pharmaceutical (Endo International plc)
    • 9.2.10. Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Treatment-resistant Depression Treatment Market, report scope
  • TABLE 2. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
  • TABLE 4. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 5. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Treatment-resistant Depression Treatment Market
  • TABLE 70. List of primary sources, used in the study of global Treatment-resistant Depression Treatment Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Treatment-resistant Depression Treatment Market, research methodology
  • FIG 2. Global Treatment-resistant Depression Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Treatment-resistant Depression Treatment Market, key trends 2021
  • FIG 5. Global Treatment-resistant Depression Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Treatment-resistant Depression Treatment Market, porters 5 force model
  • FIG 7. Global Treatment-resistant Depression Treatment Market, pest analysis
  • FIG 8. Global Treatment-resistant Depression Treatment Market, value chain analysis
  • FIG 9. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Treatment-resistant Depression Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Treatment-resistant Depression Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable